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Culture filtrate protein 10 (CFP-10) from Mycobacterium tuberculosis is a well-characterized immunodomi-
nant 10-kDa protein antigen known to elicit a very potent early gamma interferon response in T cells from M.
tuberculosis-infected mice and humans. The sequence of the Mycobacterium leprae homologue of CFP-10 shows
only 40% identity (60% homology) at the protein level with M. tuberculosis CFP-10 and thus has the potential
for development as a T- or B-cell reactive antigen for specific diagnosis of leprosy. Antisera raised in mice or
rabbits against recombinant M. leprae and M. tuberculosis CFP-10 proteins reacted only with homologous
peptides from arrays of overlapping synthetic peptides, indicating that there was no detectable cross-reactivity
at the antibody level. Sera from leprosy and tuberculosis patients were also specific for the homologous protein
or peptides and showed distinct patterns of recognition for either M. leprae or M. tuberculosis CFP-10 peptides.
At the cellular level, only 2 of 45 mouse T-cell hybridomas raised against either M. leprae or M. tuberculosis
CFP-10 displayed a cross-reactive response against the N-terminal heterologous CFP-10 peptide, the region
that exhibits the highest level of identity in the two proteins; however, the majority of peptide epitopes
recognized by mouse T-cell hybridomas specific for each protein did not cross-react with heterologous peptides.
Coupled with the human serology data, these results raise the possibility that peptides that could be used to
differentiate infections caused by these two related microorganisms could be developed. Immunohistochemical
staining of sections of M. leprae-infected nude mouse footpads resulted in strongly positive staining in
macrophages and dendritic cells, as well as weaker staining in extracellular areas, suggesting that M. leprae
CFP-10, like its homologue in M. tuberculosis, is a secreted protein.
The number of cases of leprosy worldwide has been reduced
dramatically through aggressive World Health Organization-
sponsored multidrug therapy, from approximately 10 million
cases in 1985 to a little fewer than 700,000 cases today (46–48).
However, with the unabated emergence of more than 600,000
new cases per year, there is the possibility that the source of
infection is not being addressed (16). The single greatest need
in leprosy research is the development of definitive diagnostic
tools that identify sources of leprosy and routes of transmis-
sion. The recent completion of the genome sequences of both
Mycobacterium tuberculosis (8) and Mycobacterium leprae (9)
provides an opportunity to identify leprosy-specific antigens
that might serve this purpose. A similar comparative approach
has allowed identification of genes in the RD1 region that are
deleted from Mycobacterium bovis BCG but present in M. tu-
berculosis and can therefore distinguish between infection with
M. tuberculosis and vaccination with BCG (22). Among the de-
leted antigens are two low-molecular-weight proteins, culture
filtrate protein 10 (CFP-10) (Rv3874) and ESAT-6 (Rv3875)
(3, 14). Comparative genomic analysis has revealed that genes
encoding ESAT-6- and CFP-10-like proteins are found in tan-
dem as part of a cluster of conserved genes in several species
of Mycobacterium, including M. leprae, Mycobacterium avium,
M. bovis, Mycobacterium paratuberculosis, and Mycobacterium
smegmatis, and in the relatively high-GC-content gram-pos-
itive organisms Corynebacterium diphtheriae and Streptomyces
coelicolor (40). In M. tuberculosis, the region containing the
ESAT-6 and CFP-10 genes has been duplicated five times
(designated regions 1 to 5). In M. leprae, only regions 1 and 3
are intact. Region 1 contains the M. leprae homologues of
prototype genes encoding ESAT-6 and CFP-10 (ML0049 and
ML0050, respectively), while region 3 contains the ML2531 and
ML2532 genes, which have been identified as homologues of
the genes encoding ESAT-6 and CFP-10, respectively, since
they are located in the genome at positions analogous to the
positions of the corresponding M. tuberculosis genes (42). In
region 4 of the M. leprae genome, only the single ESAT-6-like
gene ML0363 remains, while most of the genes in regions 2
and 5 are pseudogenes. Although in M. leprae the genes en-
coding ESAT-6- and CFP-10-like proteins in regions 3 and 4
exhibit relatively high levels of identity with their M. tuber-
culosis counterparts (ML2532 and Rv0287, 76% identity;
ML2531 and Rv0288, 70% identity; and ML0363 and Rv3444c,
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71% identity), region 1 appears to lie in an area prone to
genetic change, as the levels of identity for both homologues
are much lower at the amino acid level (ML0049 and Rv3875,
36% identity; and ML0050 and Rv3874, 40% identity).
As a consequence of the low level of homology between the
prototypic M. leprae and M. tuberculosis ESAT-6 proteins,
polyclonal antisera raised against either protein did not cross-
react with the other protein, either at the level of the whole
molecule or at the level of synthetic overlapping peptides (35).
In addition, the dominant B- and T-cell epitopes, as defined by
monoclonal antibodies and T-cell hybridomas, were found to
reside in different regions of the corresponding proteins. In
order to explore the potential of the M. leprae and M. tuber-
culosis CFP-10 homologues as future diagnostic reagents, we
performed a comparative immunological analysis by raising
and using polyclonal antiserum reagents and T-cell hybridomas
and by examining leprosy and tuberculosis (TB) patient sera.
MATERIALS AND METHODS
Production of recombinant M. leprae and M. tuberculosis CFP-10. The DNA
sequence coding for full-length M. leprae CFP-10 (previously identified as the
M. leprae lhp gene) was cloned from M. leprae genomic DNA by using Vent Pfu
DNA polymerase (New England Biolabs, Beverly, Mass.). PCR amplification
was carried out with forward primer 5-CCATATGGCAGAAATGATCACCG
AGGC-3 and reverse primer 5-TTAAGCTTGAAGTTCATCTTCGAGGAC
AAC-3) designed to introduce NdeI and HindIII sites, respectively (under-
lined), into the 5 and 3 ends of the open reading frame. The PCR product was
digested with restriction enzymes NdeI and HindIII and cloned into expression
vector pET 28a() (Novagen, Madison, Wis.), which uses a T7 promoter-driven
system to achieve high levels of expression of recombinant protein with a C-
terminal six-histidine tag. The DNA sequence of each recombinant clone was
confirmed by automated nucleotide sequencing (ABI model 377) at the Macro-
molecular Resources Laboratory, Colorado State University. Ligated products
were introduced into the Escherichia coli expression host BL21(DE3) (Invitro-
gen, Carlsbad, Calif.) by transformation. To obtain soluble recombinant CFP-10
(rCFP-10), a single positive colony was grown to the log phase (optical density at
600 nm, 0.5) in Luria-Bertani medium containing 50 g of kanamycin per ml and
was induced with 0.3 mM isopropyl--D-thiogalactopyranoside (IPTG) (Sigma
Chemical Co., St. Louis, Mo.) at 15°C for 16 h. The cells were lysed by enzymatic
digestion with lysozyme (0.5 mg/ml) and sonication in 0.5 M NaCl–50 mM
Tris-HCl (pH 8.0) buffer with protease inhibitors (2 g of aprotinin per ml, 1 g
of leupeptin per ml, 1 g of pepstatin per ml, 1 mM phenylmethylsulfonyl
fluoride) and then centrifuged to separate the supernatant and the cell pellet
fraction. The supernatant was applied onto Talon nickel affinity chromatography
resin (Clontech, Palo Alto, Calif.) and eluted with 50 mM imidazole (24); this
was followed by dialysis. Purified proteins were passed over a Detoxi-Gel column
(Pierce Chemical, Rockford, Ill.) to remove endotoxin. The lipopolysaccharide
content as measured by the Limulus amoebocyte lysate test (BioWhittaker,
Walkersville, Md.) was less than 2 ng/mg of protein. The protein concentration
was estimated by using the bicinchoninic assay (Pierce) (32), and the recombi-
nant protein was analyzed by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (21). Purified M. tuberculosis rCFP-10 (7) was a gift from Marila
Gennaro of the Public Health Research Institute, Newark, N.J.
Synthesis of CFP-10 peptides. Eighteen 15-mer peptides, overlapping by five
amino acids and covering the entire 100-amino-acid M. leprae and M. tuberculosis
CFP-10 sequences (p1 to p18), were synthesized by using solid-phase pin tech-
nology (Mimotopes, San Diego, Calif.). All the peptides were dissolved in sterile
distilled water at a concentration of 2 mg/ml and stored frozen at 70°C until
they were used. Stock peptide solutions for T-cell assays were diluted to obtain
a concentration of 2 g/25 l in RPMI medium.
Production of polyclonal antibodies and MAbs to rCFP-10. Polyclonal antisera
were raised in BALB/c mice (Harlan, Indianapolis, Ind.) that were immunized
with an emulsion containing 50 g of either M. leprae or M. tuberculosis rCFP-10
in phosphate-buffered saline (PBS)–incomplete Freund’s adjuvant (IFA) (1:1) at
two abdominal sites subcutaneously. Booster injections consisting of 50 g of
antigen in an IFA emulsion were administered every 3 weeks, and test bleed
samples were obtained and used for an enzyme-linked immunosorbent assay
(ELISA) after the first and second booster injections. Rabbit polyclonal anti-
serum to M. leprae rCFP-10 was raised in an outbred rabbit (Western Oregon
Rabbit Co., Philomath, Oreg.) by injecting 100 g of the protein in an emul-
sion with IFA at multiple sites subcutaneously or intramuscularly four separate
times spaced 2 to 3 weeks apart. Monoclonal antibodies (MAbs) were produced
by a standard protocol (49) by using the myeloma B-cell line SP2/0 (30). MAbs
2A6.2C2 (immunoglobulin G1 [IgG1]), 3A10.2C8 (IgG1), and 5B9.1G9 (IgG1)
were produced as cell culture supernatants. MAb CS-01 (15), specific for the
major 10-kDa antigen GroES (ML0380), was used as a positive control.
Human serum samples. Sera from both leprosy and TB patients were selected
from anonymous serum samples stored at the Department of Microbiology,
Yonsei University College of Medicine, Seoul, Republic of Korea. Approval for
the use of these serum samples was given by the internal review boards at Yonsei
University College of Medicine and Colorado State University, and the sera were
used in accordance with federal rules for the use of human sera. A set of serum
samples was screened for the presence of antibodies to either the M. leprae or M.
tuberculosis CFP-10 whole protein, and only sera showing relatively strong reac-
tivity to each antigen were chosen for further analysis in this study. For leprosy
patients, only serum samples from lepromatous patients were included; the
clinical diagnosis for four patients was three LL (the bacillary indices were 4.2,
5.0, and 4.8 for patients A, B, and C, respectively) and one BL (the bacillary
index was 3.8 for patient D). For TB patients, only sera from pulmonary TB
patients whose sputum cultures were positive were used in this study.
ELISA. For the assay involving animal immune sera, ELISA plate wells (Im-
mulon 4 96-well plates; Dynex Technologies, Chantilly, Va.) were coated with 0.5
g of M. leprae or M. tuberculosis rCFP-10 or with 5 g of synthetic peptide in
100 l of 0.1 M sodium bicarbonate buffer (pH 9.0) overnight at 4°C. The plates
were blocked with 1% bovine serum albumin (BSA) in PBS (pH 7.4) containing
0.05% Tween 80 (PBS/T) for 1 h, and this was followed by addition of 100-l
portions of dilutions of primary MAbs or polyclonal antibodies diluted in the
same buffer for 2 h. The wells were washed with PBS/T five times and incubated
with 100 l of a 1:2,000 dilution of secondary anti-mouse or anti-rabbit IgG-
alkaline phosphatase-conjugated antibody (Sigma) for 2 h. After the wells were
washed five times with PBS, 100 l of p-nitrophenylphosphate substrate (Kirke-
gaard and Perry Labs, Gaithersburg, Md.) was added, and the plates were
incubated until color developed. The plates were read at 405 nm by using a
Bio-Rad model 2550 plate reader.
For assays involving human sera, antibodies to recombinant proteins and
peptides were detected as described by Voller et al. (43), with minor modifica-
tions (6). Briefly, both recombinant antigens and synthetic peptides were diluted
to obtain a concentration of 1.0 mg/ml in PBS (pH 7.2) and were solubilized by
using a probe sonicator. Each antigen or peptide was then diluted to obtain a
concentration of 5 g/ml in 0.1 M carbonate-bicarbonate buffer (pH 9.6), and
100 l of the diluted antigen was added to wells of 96-well flat-bottom ELISA
plates (Costar, Acton, Mass.) and incubated overnight at 4°C for coating. Un-
bound antigens and peptides were washed away by using PBS/T four times, and
the wells were blocked with a solution containing 1% BSA in PBS/T. Serum
samples were diluted 1:200 for leprosy patients and 1:300 for TB patients in
PBS/T containing 5% goat serum (Invitrogen). After incubation for 2 h, horse-
radish peroxidase-conjugated goat anti-human IgG (Calbiochem, San Diego,
Calif.) diluted 1:10,000 in PBS/T containing 5% goat serum was added and
incubated for 2 h. The substrate o-phenylenediamine (Sigma) was added and
allowed to develop. The enzyme reaction was stopped by adding 2.5 M H2SO4
after 15 min, and the absorbance at 490 nm was determined. Each serum was
tested in duplicate, and the mean absorbance for control (no antigen) wells was
subtracted from that for antigen-coated wells before analysis.
Western blotting. Approximately 0.5 g of the recombinant form of each
CFP-10 was separated by sodium dodecyl sulfate—15% polyacrylamide gel elec-
trophoresis and transferred to nitrocellulose membranes as described previously
(37). The native subcellular fractions of M. leprae (cytosol, membrane, and cell
wall protein fractions) were prepared as previously described (23) and were
loaded onto the membranes at a concentration of 30 g per lane. The mem-
branes were blocked with 1% BSA in PBS/T, incubated with polyclonal mouse
serum (1:2,000), mouse MAb supernatant (1:20), or rabbit polyclonal serum
(1:10,000) raised against either M. leprae or M. tuberculosis CFP-10 overnight
with gentle rocking. To detect native CFP-10, a purified IgG fraction of rabbit
anti-CFP-10 (final dilution of a 1-mg/ml solution, 1:1,000) was used. The mem-
branes were washed with PBS/T and incubated with secondary anti-mouse or
anti-rabbit IgG-alkaline phosphatase-conjugated antibody (Sigma). The sub-
strates nitroblue tetrazolium and 5-bromo-4-chloro-3-indolylphosphate (BCIP)
(Sigma) were used for color development.
Immunohistological staining of M. leprae-infected nude mouse footpad tissue.
M. leprae isolate Thai-53 was maintained by serial passage in the footpads of
athymic BALB/c nu/nu nude mice (Harlan) (38). The mice were inoculated on
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the plantar surface of both hind feet with 1  107 freshly harvested bacilli in 50
l of 7H12 medium (Difco, Detroit, Mich.). The tissues used for these studies
were harvested after about 6 months of growth, when the footpads were mod-
erately enlarged (0.5 to 1 g) and contained numerous rapidly growing bacilli. To
prepare the tissues for histological study, the outer skin was removed, and the
lepromatous granuloma on the bottom of each foot was scooped away from the
bone with a sterile scalpel. The excised tissue was then fixed in 10% neutral
formalin overnight and processed for paraffin sectioning. Uninoculated nude
mouse tissue was handled just like the infected material and was used as a normal
control. Serial 5-m sections from both M. leprae-infected and noninfected
footpads were cut by using the embedded tissue and placed on glass slides for
staining. The paraffin was removed by using EZ-DeWax solution (BioGenex, San
Ramon, Calif.), and an antigen retrieval procedure was performed by using Citra
antigen retrieval solution (BioGenex) according to the manufacturer’s protocol.
Endogenous tissue peroxidase was inactivated by incubation with a peroxidase
blocking reagent (InnoGenex, San Ramon, Calif.) for 5 min at room tempera-
ture, and nonspecific binding was blocked by incubating the sections for 30 min
with 5% mouse serum (Sigma) in PBS (pH 7.4). Sections were incubated over-
night at 4°C with rabbit polyclonal antibody against CFP-10 (1:2,000 dilution) or
normal rabbit IgG antibody (Santa Cruz Biotechnology, Santa Cruz, Calif.)
diluted in PBS–3% BSA as a control. The sections were washed with PBS–0.5%
Tween 20 three times (15 min each). The secondary antibody, a polyclonal
anti-rabbit IgG conjugated with the enzyme horseradish peroxidase (Serotec,
Raleigh, Calif.) diluted 1:200 in PBS–3% BSA, was incubated for 40 min at room
temperature. The sections were washed with PBS–0.5% Tween 20. After wash-
ing, specific binding of the antibodies was visualized by using the substrate AEC
(BioGenex), which produced a reddish color. Sections were counterstained with
hematoxylin (BioGenex) and were mounted by using crystal mount (Biomeda
Corp., Foster City, Calif.).
Generation of CFP-10-specific T-cell hybridomas and IL-2 assay. T-cell hy-
bridomas specific for M. leprae and M. tuberculosis rCFP-10 were generated as
previously described (35). Briefly, three mice were immunized with 40 g of M.
leprae or M. tuberculosis rCFP-10 in IFA by injecting 25 l into the hind footpad
and the remainder at the base of the tail. Five days after immunization, the
draining lymph nodes (popliteal, inguinal, and periaortic) were harvested to
obtain lymph node cells, which were then restimulated in vitro with antigen-
pulsed bone marrow-derived dendritic cells by using 5 g of rCFP-10 per well.
After 2 days of culture, the cells were harvested from the wells, fused with the
T-cell fusion partner BW (45), and plated in 10 96-well plates. Clones that
grew in individual wells were screened by using a BALB/c mouse-derived B-cell
lymphoma line, A20 (19), pulsed with 0.5 g of rCFP-10 per well. The respond-
ing T-cell hybridomas were selected by assaying 24-h culture supernatants by
using paired rat MAbs specific for mouse interleukin-2 (IL-2) (Pharmingen/BD,
San Diego, Calif.) in a capture ELISA. For antigen presentation studies, we
prepared microculture wells containing 250 l of culture medium (RPMI 1640
supplemented with 10% fetal calf serum, 5  105 M 2-mercaptoethanol
[Sigma], and a nutrient cocktail described previously [18]), 5  104 T-cell hy-
bridomas, 5  104 antigen-presenting cells (APC), and a known amount of
peptide antigen in flat-bottom microtiter wells in a 96-well plate. T-cell hybrid-
omas were also tested with the overlapping M. leprae and M. tuberculosis CFP-10
peptides at a concentration of 2 g/well (or serial dilutions in dose-response
studies) presented by APC bearing defined class II molecules to identify T-cell
peptide epitopes and class II restriction elements. Mutant B-cell lymphoma lines
bearing either I-Ad alone (M12.B5) or I-Ed alone (M12.A2) (13) were used for
this analysis.
FIG. 1. Sequence alignment of M. leprae CFP-10 (ML0050) and
M. tuberculosis CFP-10 (Rv3874). Identical amino acids are indicated
by colons, conservative substitutions are indicated by periods, and non-
conservative substitutions are indicated by spaces.
FIG. 2. Reactivities of polyclonal anti-M. leprae CFP-10 and anti-
M. tuberculosis CFP-10 with homologous and heterologous CFP-10 as
determined by ELISA. M.l. anti-M.l. CFP-10, M. leprae anti-M. leprae
CFP-10; M.l. anti-Mtb CFP-10, M. leprae anti-M. tuberculosis CFP-10;
Mtb anti-Mtb CFP-10, M. tuberculosis anti-M. tuberculosis CFP-10; Mtb
anti-M.l. CFP-10, M. tuberculosis anti-M. leprae CFP-10; Ab, antibody;
O.D. 405 nm, optical density at 405 nm.
FIG. 3. Western blot of M. leprae purified rCFP-10 (lanes 1, 3, 5, 7,
and 9) and M. tuberculosis purified rCFP-10 (lanes 2, 4, 6, 8, and 10)
with MAbs and polyclonal antibodies. Lanes 1 and 2 contained equiv-
alent amounts of the proteins electrophoresed on a 15% polyacryl-
amide gel and silver stained; lanes 3 and 4 were probed with rabbit
polyclonal antiserum against M. leprae CFP-10 (rabbit Ml CFP-10)
(1:10,000 dilution); lanes 5 and 6 were probed with mouse polyclonal
antiserum against M. leprae CFP-10 (mouse Ml CFP-10) (1:2,500 di-
lution); lanes 7 and 8 were probed with mouse MAb 3A10.2C8 specific
for peptides p5 and p6 (1:20 dilution of culture supernatant); and lanes
9 and 10 were probed with the mouse polyclonal antiserum against
M. tuberculosis CFP-10 (mouse Mtb CFP-10) (1:2,500 dilution).
FIG. 4. Western blot of subcellular fractions of M. leprae to detect
native CFP-10. Lanes 1 and 6, M. leprae cytosol; lane 2, M. leprae
membrane; lane 3, M. leprae cell wall; lane 4, M. tuberculosis culture
filtrate protein; lane 5, M. tuberculosis cytosol. Approximately 30 g of
protein was electrophoresed in lanes 1 to 5, and 1 g of protein was
electrophoresed in lane 6. Lanes 1 to 5 were probed with purified IgG
from rabbit polyclonal anti-M. leprae CFP-10, while lane 6 was probed
with MAb CS-01 specific for the 10-kDa GroEs protein. mw, molecular
weight (in thousands).
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RESULTS
Polyclonal antisera to M. leprae and M. tuberculosis CFP-10
show little cross-reactivity. A comparison of the alignment of
the sequences of the two 100-amino-acid proteins (Fig. 1)
showed that there was only 40% identity (60% homology).
Although there was identity at seven of the first nine amino
acids at the N terminus (MAEMITEAA; 77% identity; under-
lining indicates that the amino acids were the same in both
proteins), this region is the only region with four or more
identical sequential amino acids. The remainder of the se-
quence alignment showed that there were only one, two, or (in
one case at the C terminus) three identical amino acids to-
gether, but the sequences of identical amino acids were inter-
rupted by stretches of conserved and nonconserved amino acid
differences throughout the proteins. Other than the region at
the N terminus, there appeared to be very few conserved re-
gions capable of eliciting cross-reactive antibodies between the
two CFP-10 proteins. The reactivity of the mouse antisera to
the homologous and heterologous proteins confirmed this con-
clusion. The polyclonal antisera produced after the third im-
munization had high titers to the homologous protein im-
munogen, and these antisera reacted only very weakly to the
heterologous proteins as determined by the ELISA (Fig. 2) at
low serum dilutions. On the other hand, rabbit antisera raised
against M. leprae CFP-10 showed no cross-reactivity against
M. tuberculosis CFP-10 as determined by either ELISA (see
Table 2) or Western blotting (Fig. 3), even when they were
tested at a low dilution (1:500). Native M. leprae CFP-10 was
detected by Western blotting in all three native subcellular
fractions by using a purified IgG fraction of the rabbit poly-
clonal anti-CFP-10, which showed that the strongest signal was
in the cell wall and the weakest signal was in the membrane
fraction (Fig. 4). For comparative purposes, a blot of the 10-
kDa GroES protein probed with MAb CS-01 is shown in Fig.
4. No cross-reactivity was detected in corresponding M. tuber-
culosis fractions of culture filtrate protein or cytosol.
Overlapping 15-mer peptides covering the entire M. leprae
and M. tuberculosis CFP-10 proteins were synthesized (Table
1) in order to identify B-cell epitopes and to determine if
cross-reactive linear B-cell epitopes existed. The polyclonal
antibodies revealed distinct reactivity patterns with each of the
homologous peptides (Table 2); however, no cross-reactivity of
each serum with any of the heterologous peptides was ob-
served (data not shown). Despite this, there was a consistently
low level of cross-reactivity of each mouse polyclonal serum
with the heterologous whole protein, suggesting that while
there was no cross-reactive recognition of linear peptide epi-
topes, there were conformational epitopes that were similar
enough to account for the limited cross-reactivity observed.
Certain homologous peptides were recognized by both mouse
TABLE 1. Synthetic overlapping 15-mer CFP-10 M. leprae
and M. tuberculosis peptides
Peptide Aminoacids Species Sequence
a %
Identity
p1 1–15 M. leprae MAEMITEAAILTQQA 67
M. tuberculosis MAEMKTDAATLAQEA
p2 6–20 M. leprae TEAAILTQQAAQFDQ 47
M. tuberculosis TDAATLAQEAGNFER
p3 11–25 M. leprae LTQQAAQFDQIASGL 33
M. tuberculosis LAQEAGNFERISGDL
p4 16–30 M. leprae AQFDQIASGLSQERN 20
M. tuberculosis GNFERISGDLKTQID
p5 21–35 M. leprae IASGLSQERNFVDSI 20
M. tuberculosis ISGDLKTQIDQVEST
p6 26–40 M. leprae SQERNFVDSIGQSFQ 27
M. tuberculosis KTQIDQVESTAGSLQ
p7 31–45 M. leprae FVDSIGQSFQNTWEG 40
M. tuberculosis QVESTAGSLQGQWRG
p8 36–50 M. leprae GQSFQNTWEGQAASA 40
M. tuberculosis AGSLQGQWRGAAGTA
p9 41–55 M. leprae NTWEGQAASAALGAL 40
M. tuberculosis GQWRGAAGTAAQAAV
p10 46–60 M. leprae QAASAALGALGRFDE 47
M. tuberculosis AAGTAAQAAVVRFQE
p11 51–65 M. leprae ALGALGRFDEAMQDQ 47
M. tuberculosis AQAAVVRFQEAANKQ
p12 56–70 M. leprae GRFDEAMQDQIRQLE 40
M. tuberculosis VRFQEAANKQKQELD
p13 61–75 M. leprae AMQDQIRQLESIVDK 27
M. tuberculosis AANKQKQELDEISTN
p14 66–80 M. leprae IRQLESIVDKLNRSG 20
M. tuberculosis KQELDEISTNIRQAG
p15 71–85 M. leprae SIVDKLNRSGGNYTK 20
M. tuberculosis EISTNIRQAGVQYSR
p16 76–90 M. leprae LNRSGGNYTKTDDEA 27
M. tuberculosis IRQAGVQYSRADEEQ
p17 81–95 M. leprae GNYTKTDDEANQLLS 40
M. tuberculosis VQYSRADEEQQQALS
p18 86–100 M. leprae TDDEANQLLSSKMNF 53
M. tuberculosis ADEEQQQALSSQMGF
a Boldface type indicates identity.






CFP-10 p1 p2 p3 p4 p5 p6 p7 p8 p9 p10 p11 p12 p13 p14 p15 p16 p17 p18
Mouse anti-M. leprae
CFP-10
b /    /     /   /      
Rabbit anti-M. leprae
CFP-10
      /         /    
Mouse anti-M. tuber-
culosis CFP-10
/    /           / /   
3A10.2C8                    
a 3A10.2C8, mouse MAb specific for M. leprae CFP-10.
b , optical density as determined by ELISA, 4.00; , optical density, 1.50 to 4.00; , optical density, 0.50 to 1.49; /, optical density, 0.20 to 0.49; ,
background reading (optical density, 	0.20). The polyclonal sera were tested at a 1:500 dilution, and the MAb was tested at a 1:2 dilution. There was no response of
either polyclonal antisera or the MAb to any heterologous peptide.
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antisera (notably, peptides p6, p7, p8, p10, and p16), while two
peptides, p1 (which had the highest level of identity, 67%) and
p13, were not recognized by either antiserum. Most of the
peptides recognized by the mouse polyclonal anti-M. leprae
CFP-10 serum were also recognized by the rabbit polyclonal
serum, although the strength of the reactivity varied with each
peptide. These two antisera gave strong and very similar re-
sponses to M. leprae CFP-10 peptides p2 and p10, while the
rabbit antisera gave additional strong responses to M. leprae
peptides p16 and p17. Interestingly, none of the antisera re-
acted with peptide p18, whereas the mouse polyclonal serum
against M. tuberculosis CFP-10 showed a fairly strong response
to this C-terminal peptide. The reactive peptides occurred in
regions that were more hydrophilic and had potential B-cell
epitopes, as predicted by using a Kyte-Doolittle hydrophobicity
plot (20) and the Jameson-Wolf antigenic index (17), respec-
tively, while peptide p1 was decidedly more hydrophobic, per-
haps accounting for its lack of recognition by all polyclonal
antibodies. Of the three MAbs, only MAb 3A10.2C8 showed a
response to any of the peptides, responding strongly to homol-
ogous peptides p5 and p6, indicating that the linear B-cell
epitope recognized is common to both peptides (Table 2),
probably lying within peptide 26SQERNFVDSI35. These pep-
tides have low levels of identity (20 and 27%, respectively) to
the corresponding M. tuberculosis CFP-10 peptides, but they
occur in a region predicted to be very hydrophilic and to have
a high probability of containing B-cell epitopes.
Human serological reactivity to CFP-10 peptides. Leprosy
and TB patient sera that exhibited the greatest responses to
M. leprae CFP-10 and M. tuberculosis CFP-10, respectively,
were used to examine the reactivity with the 18 peptides. The
leprosy patient sera reacted specifically only against the ho-
mologous M. leprae CFP-10 protein and peptide set, while the
TB patient sera similarly reacted only against the homologous
protein and peptides (Tables 3 and 4). Although the sera of the
majority of individuals recognized only one or a few peptides,
certain peptides were recognized by sera from multiple pa-
tients. Two of four of the leprosy patient serum samples rec-
ognized peptides p6 and p16, while peptide p15 was recognized
by three individual samples. The TB patient sera seemed to
react with more peptides overall, and at least two patient
samples reacted with peptides p3, p5, p6, p10, p14, and p18. All
of the sera of TB patients in this group reacted with peptide
p18. As was the case with the animal sera, peptides p1 and p13
TABLE 3. Representative leprosy (n 
 4) and TB (n 
 1) patient
serum responses to M. leprae and M. tuberculosis rCFP-10













M. leprae CFP-10 1.94 1.87 0.96 1.81 0.11
M. tuberculosis CFP-10 0.07 0.01 0.01 0.01 1.39
M. leprae p1 0.02 0.01 0.01 0.03 0.01
M. leprae p2 0.08 0.08 0.04 0.01 0.01
M. leprae p3 0.09 0.09 0.10 0.01 0.01
M. leprae p4 0.01 0.01 0.01 0.01 0.01
M. leprae p5 0.01 0.01 0.01 0.01 0.01
M. leprae p6 0.46 0.44 0.10 0.06 0.01
M. leprae p7 0.23 0.11 0.11 0.01 0.01
M. leprae p8 0.01 0.01 0.11 0.01 0.01
M. leprae p9 0.01 0.01 0.02 0.01 0.01
M. leprae p10 0.06 0.01 0.19 0.01 0.01
M. leprae p11 0.01 0.01 0.14 0.02 0.01
M. leprae p12 0.01 0.01 0.01 0.77 0.01
M. leprae p13 0.01 0.02 0.01 0.01 0.01
M. leprae p14 0.01 0.01 0.01 0.01 0.01
M. leprae p15 1.46 1.32 0.59 0.01 0.01
M. leprae p16 0.44 0.42 0.03 0.01 0.01
M. leprae p17 0.05 0.05 0.01 0.11 0.01
M. leprae p18 0.01 0.01 0.01 0.01 0.01
a Values are optical densities at 490 nm; boldface indicates positive responses.
TABLE 4. Representative TB (n 
 8) and leprosy (n 
 1) patient serum responses to M. leprae and M. tuberculosis rCFP-10





















M. tuberculosis CFP-10 1.41 1.66 1.44 1.73 1.24 1.38 0.99 1.52 0.01
M. leprae CFP-10 0.01 0.05 0.01 0.13 0.06 0.01 0.01 0.01 1.86
M. tuberculosis p1 0.01 0.01 0.01 0.08 0.01 0.01 0.01 0.26 0.01
M. tuberculosis p2 0.03 0.13 0.01 0.01 0.01 0.01 0.01 0.01 0.01
M. tuberculosis p3 0.57 1.32 0.01 0.01 0.01 0.01 0.01 0.01 0.01
M. tuberculosis p4 0.01 0.01 0.01 0.01 0.36 0.01 0.01 0.01 0.01
M. tuberculosis p5 0.18 0.05 0.68 0.01 0.01 0.24 0.01 0.01 0.01
M. tuberculosis p6 0.01 0.59 0.91 0.01 0.01 0.01 0.01 0.01 0.03
M. tuberculosis p7 0.01 0.02 0.01 0.03 0.11 0.01 0.01 0.07 0.01
M. tuberculosis p8 0.01 0.01 0.01 0.01 0.08 0.01 0.01 0.01 0.01
M. tuberculosis p9 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
M. tuberculosis p10 0.93 0.22 0.29 0.52 0.01 0.01 0.01 0.01 0.01
M. tuberculosis p11 0.01 0.74 0.01 0.01 0.01 0.01 0.01 0.01 0.01
M. tuberculosis p12 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
M. tuberculosis p13 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
M. tuberculosis p14 0.01 0.27 0.01 0.01 0.01 0.37 0.01 0.01 0.01
M. tuberculosis p15 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
M. tuberculosis p16 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
M. tuberculosis p17 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
M. tuberculosis p18 0.57 1.54 0.27 0.16 0.17 1.26 0.51 1.31 0.01
a Values are optical densities at 490 nm, boldface indicates positive responses.
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showed no response with either leprosy or TB patient sera,
except for a fairly weak response against p1 by serum from a
single TB patient.
Comparison of T-cell epitopes of M. leprae and M. tubercu-
losis CFP-10. Fifteen T-cell hybridomas produced IL-2 when
they were presented with M. leprae CFP-10, and all of them
used the I-Ad class II molecule to present the processed whole
molecule. Four of these T-cell hybridomas were able to recog-
nize peptides from the panel of overlapping 15-mers (Table 5).
Two of the hybridomas, 5D4 and 8D11, recognized peptide p2
(amino acids 6 to 20), while hybridomas 1G4 and 6G7 recog-
nized peptides p1 (amino acids 1 to 15) and p2, although both
exhibited greater responses to peptide p1, suggesting that a
portion of the epitope in p2 is truncated. Hybridoma 1G4 was
also able to produce IL-2 in response to M. tuberculosis CFP-10
peptide p1, but it did not respond at all to M. tuberculosis
CFP-10 peptide p2. These results suggest that the critical
amino acid residues necessary for either binding to class II or
interacting with the T-cell receptor reside in M. tuberculosis
peptide p1 but that changes in p2 disrupt one of these inter-
actions.
Thirty independently derived T-cell hybridomas were gen-
erated that produced IL-2 in response to whole M. tuberculosis
CFP-10 presented by APC. Unlike the limited responses to
peptides seen with the M. leprae CFP-10-specific T-cell hybrid-
omas, all of the M. tuberculosis CFP-10-specific hybridomas
were capable of peptide recognition (Table 6). Four distinct
peptide regions were recognized. Eight hybridomas recognized
peptides p1 and p2, and like M. leprae CFP-10-specific hybrid-
omas 1G4 and 6G7, all responded more strongly in dose-
response presentation assays by producing higher levels of IL-2
in response to p1 than in response to p2. Only one of the
hybridomas, 4E9, was capable of cross-reactivity, responding to
M. leprae peptide p1 but not to p2. Two hybridomas, 5B12 and
6D5, recognized peptide p4 (amino acids 16 to 30). Nine hy-
bridomas recognized peptide p9 (amino acids 41 to 55), while
two other hybridomas, 5B7 and 5D9, recognized an epitope
shared by two peptides, p9 and p10. Nine hybridomas re-
sponded equally well to peptides p15 (amino acids 71 to 85)
and p16 (amino acids 76 to 90), indicating that amino acids
common to both peptides were recognized. The relative
strengths of the responses of hybridomas to each of the four
peptides were examined by preparing a dose-response curve in
antigen presentation experiments (Fig. 5). Hybridomas react-
ing with peptide p9 and with peptides p15 and p16 responded
at least 10-fold better than hybridomas reacting with peptide
p1 or p4. There were no differences in the dose-response
curves for hybridomas reacting with peptides p15 and p16,
indicating that the abilities of these peptides to stimulate were
equivalent. When mutant B-cell lines expressing either I-Ad
(M12.B5) or I-Ed (M12.A2) were used, all of the CFP-10
hybridomas were found to recognize peptides presented by the
I-Ad class II molecule (data not shown). Other than hybrid-
omas 1G4 and 4E9, none of the T-cell hybridomas showed any
recognition of heterologous peptides (data not shown).
Immunohistological staining of CFP-10 in M. leprae-infected
nude mouse footpads. Tissue sections from footpads of M. lep-
rae-infected nu/nu mice were stained with hematoxylin and
eosin with or without rabbit polyclonal antibody recognizing
M. leprae CFP-10 (Fig. 6). Hematoxylin and eosin staining
revealed a non-T-cell type of granulomatous structure, and
FIG. 5. Comparison of M. tuberculosis CFP-10-specific T-cell hy-
bridoma responses to the four peptide epitopes recognized. T-cell
hybridomas were cultured with the antigen-presenting B-cell line A20
pulsed with serial twofold dilutions of peptide (4 g to 8 ng per well)
in a dose-response experiment. The hybridomas examined were 7F12
and 3A2 (peptide p1 specific), 5B12 and 6D5 (p4 specific), 1G10 and
5H9 (p9 specific), and 6A3 and 9H1 (p15 and p16 specific). The IL-2
secretion in response to antigen stimulation was measured in 24-h
culture supernatant by a capture ELISA. O.D. 450 nm, optical density
at 450 nm.
TABLE 5. Reactivities of M. leprae CFP-10-specific T-cell
hybridomas to M. leprae CFP-10 and M. leprae










1G4 a    
6G7     
5D4     
8D11     
a , optical density, 4.00; , optical density, 1.00 to 3.99; , optical
density, 0.20 to 0.99; , background reading (optical density, 	0.20; corresponds
to	1 pg of IL-2 per ml). An optical density of1.00 indicates production of20
pg of IL-2 per ml by T-cell hybridomas.
TABLE 6. Peptide reactivities of 30 M. tuberculosis
CFP-10-specific T-cell hybridomas
T-cell hybridoma(s) Peptide(s) Cross-reactivity
3A2, 5A5, 5A6, 5A12, 7F12, 8E8, 10A6 p1  p2a No
4E9 p1  p2, M. leprae
p1 cross-reactive
Yes
5B12, 6D5 p4 No
1G10, 2B12, 3C6, 4D12, 4E10, 5H9,
6G10, 8G10, 10G12
p9 No
5B7, 5D9 p9 and p10 No
2A10, 2H5, 3G11, 5C3, 6A3, 6F5, 9D7,
9H1, 10B8
p15 and p16 No
a The optimal peptide concentrations used to induce stimulation of T-cell
hybridomas were approximately 7 to 15 M. The amount of IL-2 secreted in 24-h
culture supernatants, as measured by capture ELISA, was 20 pg/ml, while
stimulation with the corresponding non-cross-reactive M. leprae peptide resulted
in background levels of 	1 pg/ml.
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there were many acid-fast bacilli inside the cells when they
were stained with Kinyoun acid-fast stain. Many of the cells
within the granuloma were stained with MAb DC205, which is
fairly specific for dendritic cells, and MAb MAC-3, which
stains cells of the macrophage lineage (data not shown), and
these areas were strongly positive for CFP-10. CFP-10 staining
was found to be localized both within the cytoplasm of cells
and extracellularly, although the extracellular staining was dif-
fuse and weaker than the intracellular staining. There was no
background staining of control uninfected nu/nu mouse foot-
pad sections with the rabbit anti-CFP-10 antiserum.
DISCUSSION
In this study, we characterized the major B- and T-cell epi-
topes recognized by immune sera and T-cell hybridomas gen-
erated against the M. tuberculosis and M. leprae CFP-10 pro-
teins. At the antibody level, each mouse polyclonal antiserum
showed a distinct pattern of recognition of the homologous set
of peptides; for each protein there was no cross-reactivity of
the serum with any of the peptides of the other protein, and
there were only very weak cross-reactive responses against the
whole protein. In contrast to the mouse polyclonal antiserum,
which showed low levels of cross-reactivity to the heterologous
whole CFP-10 protein in ELISA and Western blots, the rabbit
polyclonal antiserum showed no cross-reactivity by either
method, even when a dilution as low as 1:500 was used. The
peptides that induced the greatest responses for each CFP-10
were in regions of the molecule that had the highest hydrophi-
licity index, indicating that there are sites on the protein that
are more likely to be exposed to the surface and thus bear
potential B-cell epitopes. Despite the overall similarity in the
hydrophilicity profiles for the two CFP-10 proteins, there were
peptides that induced preferentially greater responses for each
protein. For the M. leprae CFP-10 antiserum, homologous pep-
tides p2, p8, p10, and p15 were much more reactive than the M.
tuberculosis CFP-10 antiserum to the corresponding M. tuber-
culosis peptides; conversely, M. tuberculosis peptides p12, p17,
and p18 were more strongly recognized by anti-M. tuberculosis
CFP-10 serum than their M. leprae counterparts were. Despite
having the highest levels of homology, peptides at the N and C
termini (p1, 80% homology; and p18, 67% homology) were not
cross-reactive; peptide p1 did not even induce an antibody
response, probably due to its greater hydrophobicity.
The lack of immunologic cross-reactivity for peptides at the
B-cell level could be useful in differentiating M. leprae infec-
tions from M. tuberculosis infections. Indeed, the responses of
leprosy and TB serum samples with the M. leprae and M.
tuberculosis CFP-10 proteins support the possibility that the
FIG. 6. Immunohistological staining of M. leprae-infected nu/nu mouse footpad sections with polyclonal rabbit anti-M. leprae CFP-10. Forma-
lin-fixed tissue embedded in paraffin was cut into 5-m sections and stained by conventional methods. (A) Kinyoun method for acid-fast staining,
showing specific acid-fast staining of bacilli within (arrow) and outside (arrowhead) necrotic cell pockets. Magnification, 200. (B) Hematoxylin
and eosin staining, showing a pocket of necrotic cells (arrow) and extensive infiltration of foamy-like macrophages (arrowhead). Magnification,
200. (C and D) Immunohistochemistry with a rabbit polyclonal antibody against M. leprae CFP-10, indicated by dark red staining in the center
of cells within the granuloma (arrows). Magnification, 400.
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differences can be exploited. Both leprosy and TB sera were
specific for the homologous CFP-10 and, like the animal anti-
sera, showed no cross-reactivity against any of the heterolo-
gous peptides. Not all patient sera produced a strong response
against the whole CFP-10 proteins, and only the sera that had
a relatively high titer against the whole protein were tested
further, as weaker responders gave indeterminate or negative
peptide responses. The recognition of peptides by human se-
rum samples was generally weaker overall, but this was not
unexpected since our assay detects the antibody response to a
single protein among the many antigens produced by the mi-
croorganism in a natural infection, as opposed to the stronger
peptide responses generated by immunizing animals with a
single protein antigen. Nevertheless, some individuals in each
group responded well to one or more peptides, and the indi-
viduals showed distinct differences in peptide preference. Lep-
rosy patient sera reacted well with M. leprae CFP-10 peptides
p15 and p16, which mirrored the mouse and rabbit serum
responses, whereas none of the sera from TB patients re-
sponded to either of these two peptides. Likewise, mouse poly-
clonal antisera against M. tuberculosis CFP-10 responded quite
well to the homologous peptide p18, and the sera of all of the
TB patients in this group reacted with p18, some quite strongly,
whereas both rabbit and mouse antisera against M. leprae CFP-
10, as well as the four leprosy patient sera, did not respond at
all to the homologous peptide p18. One would expect that
there are differences in peptide responses against the two
forms of CFP-10 at the T-cell level as well, a prospect which we
are currently studying.
An analysis of the T-cell responses against the two CFP-10
proteins showed that multiple peptide epitopes were recog-
nized for each protein. Although all 30 of the M. tuberculosis
CFP-10-specific T-cell hybridomas generated were found to
react with one or more peptides in four distinct regions, only 4
of the 15 M. leprae CFP-10-specific hybridomas were similarly
characterized. A similar percentage of hybridomas specific for
M. leprae ESAT-6 that remained uncharacterized with regard
to peptide epitope specificity has been observed previously
(35). It is possible that when the overlapping 15-mer M. leprae
peptide set was created, critical amino acids necessary for
peptide binding to major histocompatibility complex (MHC)
class II or for interactions with the T-cell receptor molecules
were omitted, leading to a lack of a response to peptides for
most of the hybridomas despite the excellent IL-2 production
with the whole protein. Overlapping 15-mer peptides were
synthesized in order to maximize the probability of detecting
all possible T-cell epitopes since it has been shown previously
that native processed peptides eluted from MHC class II mol-
ecules are generally 13 to 17 amino acids long (27). Generally,
for a given protein of average size, there are usually only one
or a few peptides that can be recognized as T-cell epitopes (26,
28), so the discovery of four distinct T-cell epitopes on a fairly
small protein was surprising. As was the case with M. leprae
ESAT-6 (35), all of the peptide epitopes identified in this study
were presented by the MHC class II molecule I-Ad, a bias that
may be a reflection of the higher levels of expression of this
isotype than of I-Ed on the surface of BALB/c APC (34). As for
the peptides recognized, a high percentage of T-cell epitopes
that have been described contain amphipathic structures (10),
and such structures were identified in all four peptide regions
recognized in Rv3874. Such structures were also found within
the two recognized peptides of ML0050, but the structures
were much shorter. In addition, as determined by using a
program developed by Sette et al. (29) which predicts the
ability of hexapeptides to bind to the I-Ad class II molecule
based on a common structural motif, peptides p4, p15, and 16
from Rv3874 and peptides p1 and p2 from ML0050 contain
such motifs. The limited cross-reactivity of peptide p1 was not
unexpected, since this region has the highest homology of all of
the peptides in the set. Nevertheless, the presence of only one
hybridoma that is capable of cross-reactive recognition in each
set suggests that the cross-reactive recognition between the M.
leprae and M. tuberculosis CFP-10 proteins is fairly limited,
giving hope that similar disease-specific epitopes can be de-
fined that may ultimately serve as diagnostic reagents for early
detection of leprosy in humans.
CFP-10 is found mainly as an exported protein in the culture
filtrate protein fraction of M. tuberculosis. If it is also found
mainly as a secreted protein in M. leprae, the likelihood of
finding detectable levels of it in any of the subcellular fractions
would be small. The method by which M. leprae is purified from
infected armadillo tissues includes digestion of the homoge-
nized tissue with collagenase and proteolytic enzymes and
treatment with alkali intended to remove host proteins. This
process probably leads to destruction of any secreted and cell
surface-associated proteins. Although previously M. leprae
ESAT-6 was found only in the native cell wall fraction (35), by
using a purified IgG fraction of the rabbit polyclonal anti-
CFP-10 we were able to detect CFP-10 in all three M. leprae
subcellular fractions; the largest amount was found in the cell
wall fraction, followed by the cytosol, and the protein was
barely detectable in the membrane fraction. There was no
reaction with either the culture filtrate protein or the cytosolic
fraction from M. tuberculosis. In addition, we performed in situ
immunohistological staining of M. leprae-infected nu/nu mouse
footpads. When the rabbit polyclonal anti-M. leprae CFP-10
serum was used, this reagent revealed strong staining inside
macrophages and dendritic cells within the granulomatous
structure, as well as a diffuse pattern of weaker staining of the
extracellular matrix. There was no staining of the uninfected
control nude mouse footpads. The finding that staining was
localized extensively within the cytoplasm of infected cells, as
well as extracellularly, and was not just associated with intact
bacilli was indirect evidence that the CFP-10 produced by M.
leprae is potentially secreted.
Members of the CFP-10 family have been closely linked to
the immunologically important ESAT-6 family; both CFP-10
and ESAT-6 are small proteins that are released into the cul-
ture filtrate of M. tuberculosis cultures very early in the growth
cycle, despite lacking signal peptide sequences. Two recent
studies (25, 36) verified the hypothesis proposed by van Pittius
and coworkers (40) that a cluster of conserved genes that flank
the esx and lhp genes are involved in a non-Sec-dependent
secretion apparatus for the export of ESAT-6 and CFP-10 of
M. tuberculosis, in agreement with the lack of signal sequences
in these proteins. Genetic complementation of M. bovis BCG
with M. tuberculosis genes indicated that at least 11 genes
(Rv3867 to Rv3877) are required for secretion of large
amounts of ESAT-6 and CFP-10 into the culture supernatant
(25). Rv3870 and Rv3871 are AAA class ATPases, while
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Rv3877 is a large transmembrane protein. Mutants of M. tu-
berculosis lacking these proteins cannot secrete ESAT-6 and
CFP-10. Furthermore, both ESAT-6 and CFP-10 must be in-
tact for secretion of either of the proteins (36). All of the 11
genes except Rv3872 are present in the M. leprae genome in
the same genetic arrangement. Therefore, it is believed that M.
leprae secretes ESAT-6 and CFP-10 in the same manner that
M. tuberculosis secretes these proteins. However, because of
extensive sequence differences found in the proteins encoded
in this region in M. leprae, the only way to prove this would be
to conduct similar gene complementation experiments with the
genes of M. leprae. Nevertheless, transcripts for M. leprae
CFP-10 and ESAT-6 have been shown to exist by reverse
transcription-PCR in nu/nu mouse-derived M. leprae by using
two different isolates, strains Thai-53 and 4089, and by using a
pool of human leprosy patient biopsy material (Diana Wil-
liams, National Hansen’s Disease Program, Louisiana State
University, Baton Rouge, unpublished observations).
Although the function of these proteins is unknown, both
elicit potent cell-mediated responses very early during the
course of infection (1, 7, 31, 33). Both ESAT-6 and CFP-10
have shown great promise as immunodiagnostic reagents for
TB in humans and cattle (2, 5, 39, 44). It has been shown that
combining M. tuberculosis ESAT-6 and CFP-10 in a diagnostic
test for infection or exposure to TB could provide the level of
specificity and sensitivity necessary to detect exposure to TB
(2). However, there have been recent reports suggesting that
cross-reactive recognition or high background responses to
either whole ESAT-6 or CFP-10 or their peptides may be more
common in areas where TB and leprosy are endemic, even in
healthy controls with minimal exposure to either disease (11,
12, 41). It is possible that in countries where both diseases are
endemic, there is much more exposure of otherwise healthy
individuals to a variety of pathogenic and environmental my-
cobacteria that could contribute to this phenomenon. It has
been argued that one of the reasons why BCG vaccination
appears to be less effective in areas where TB is prevalent is
that there is much more exposure to nonpathogenic mycobac-
teria found in the soil and water, in addition to disease expo-
sure (4). It is important to determine how widespread such
cross-reactive responses to ESAT-6 and CFP-10 are in the
countries where TB and leprosy are found together and to use
the non-cross-reactive peptides identified in this work as dis-
ease-specific diagnostic reagents. Thus, the low-molecular-
weight proteins of M. leprae, only a few of which are not
encoded by pseudogenes, offer great promise as specific diag-
nostic reagents for leprosy.
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